CY1125157T1 - Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη - Google Patents
Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζοληInfo
- Publication number
- CY1125157T1 CY1125157T1 CY20221100263T CY221100263T CY1125157T1 CY 1125157 T1 CY1125157 T1 CY 1125157T1 CY 20221100263 T CY20221100263 T CY 20221100263T CY 221100263 T CY221100263 T CY 221100263T CY 1125157 T1 CY1125157 T1 CY 1125157T1
- Authority
- CY
- Cyprus
- Prior art keywords
- anatrozole
- compositions containing
- injectable compositions
- containing letrozole
- composition
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 title 1
- 229960003881 letrozole Drugs 0.000 title 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 239000004626 polylactic acid Substances 0.000 abstract 1
- 229920001169 thermoplastic Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201231271A ES2390439B1 (es) | 2012-08-03 | 2012-08-03 | Composición inyectable |
| PCT/EP2013/065877 WO2014019972A1 (en) | 2012-08-03 | 2013-07-29 | Injectable compositions comprising letrozole or anastrozole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125157T1 true CY1125157T1 (el) | 2024-02-16 |
Family
ID=47046938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100263T CY1125157T1 (el) | 2012-08-03 | 2022-04-07 | Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP2879661B1 (enExample) |
| JP (1) | JP6317348B2 (enExample) |
| KR (1) | KR101892109B1 (enExample) |
| CN (1) | CN104519870B (enExample) |
| AU (1) | AU2013298705B2 (enExample) |
| BR (1) | BR112015002370B1 (enExample) |
| CA (1) | CA2880347C (enExample) |
| CL (1) | CL2015000259A1 (enExample) |
| CY (1) | CY1125157T1 (enExample) |
| DK (1) | DK2879661T3 (enExample) |
| EA (1) | EA033316B1 (enExample) |
| ES (2) | ES2390439B1 (enExample) |
| HR (1) | HRP20220537T1 (enExample) |
| HU (1) | HUE058322T2 (enExample) |
| IL (1) | IL236981B (enExample) |
| IN (1) | IN2015DN01711A (enExample) |
| LT (1) | LT2879661T (enExample) |
| MA (1) | MA37870B1 (enExample) |
| MX (1) | MX362874B (enExample) |
| MY (1) | MY194726A (enExample) |
| NZ (1) | NZ705558A (enExample) |
| PH (1) | PH12015500231A1 (enExample) |
| PL (1) | PL2879661T3 (enExample) |
| PT (1) | PT2879661T (enExample) |
| RS (1) | RS63104B1 (enExample) |
| SG (1) | SG11201500793VA (enExample) |
| SI (1) | SI2879661T1 (enExample) |
| SM (1) | SMT202200127T1 (enExample) |
| UA (1) | UA113317C2 (enExample) |
| WO (1) | WO2014019972A1 (enExample) |
| ZA (1) | ZA201501426B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) * | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| SMT202100679T1 (it) | 2010-05-31 | 2022-01-10 | Laboratorios Farmaceuticos Rovi S A | Composizioni per impianti biodegradabili in-situ iniettabili |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| PE20210047A1 (es) * | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| EP4041189B1 (en) * | 2019-10-07 | 2025-09-17 | Oak Crest Institute of Science | Orally implantable drug delivery device |
| KR102319352B1 (ko) | 2021-02-03 | 2021-10-29 | 바이오메디팜 어업회사법인 주식회사 | 첨연어의 수컷화 비율을 높이는 비호르몬적 방법 |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| WO2025153747A1 (es) * | 2024-01-17 | 2025-07-24 | Laboratorios Farmacéuticos Rovi, S.A. | Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| GB0517673D0 (en) | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| GB0517674D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| AR063120A1 (es) * | 2006-10-05 | 2008-12-30 | Panacea Biotec Ltd | Composiciones inyectables de deposito y proceso para prepararlas |
| CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| SMT202100679T1 (it) * | 2010-05-31 | 2022-01-10 | Laboratorios Farmaceuticos Rovi S A | Composizioni per impianti biodegradabili in-situ iniettabili |
| MX347014B (es) | 2010-11-24 | 2017-04-07 | Durect Corp | Composición para administración de fármaco biodegradable. |
-
2012
- 2012-08-03 ES ES201231271A patent/ES2390439B1/es active Active
-
2013
- 2013-07-29 MX MX2015001513A patent/MX362874B/es active IP Right Grant
- 2013-07-29 CN CN201380041244.8A patent/CN104519870B/zh active Active
- 2013-07-29 DK DK13742226.7T patent/DK2879661T3/da active
- 2013-07-29 EP EP13742226.7A patent/EP2879661B1/en active Active
- 2013-07-29 MY MYPI2015700311A patent/MY194726A/en unknown
- 2013-07-29 ES ES13742226T patent/ES2926715T3/es active Active
- 2013-07-29 IN IN1711DEN2015 patent/IN2015DN01711A/en unknown
- 2013-07-29 LT LTEPPCT/EP2013/065877T patent/LT2879661T/lt unknown
- 2013-07-29 EA EA201500196A patent/EA033316B1/ru unknown
- 2013-07-29 BR BR112015002370-3A patent/BR112015002370B1/pt active IP Right Grant
- 2013-07-29 HU HUE13742226A patent/HUE058322T2/hu unknown
- 2013-07-29 PT PT137422267T patent/PT2879661T/pt unknown
- 2013-07-29 JP JP2015524749A patent/JP6317348B2/ja active Active
- 2013-07-29 SM SM20220127T patent/SMT202200127T1/it unknown
- 2013-07-29 AU AU2013298705A patent/AU2013298705B2/en active Active
- 2013-07-29 NZ NZ705558A patent/NZ705558A/en unknown
- 2013-07-29 KR KR1020157005601A patent/KR101892109B1/ko active Active
- 2013-07-29 WO PCT/EP2013/065877 patent/WO2014019972A1/en not_active Ceased
- 2013-07-29 SI SI201331978T patent/SI2879661T1/sl unknown
- 2013-07-29 HR HRP20220537TT patent/HRP20220537T1/hr unknown
- 2013-07-29 SG SG11201500793VA patent/SG11201500793VA/en unknown
- 2013-07-29 RS RS20220307A patent/RS63104B1/sr unknown
- 2013-07-29 CA CA2880347A patent/CA2880347C/en active Active
- 2013-07-29 PL PL13742226T patent/PL2879661T3/pl unknown
- 2013-07-29 UA UAA201501775A patent/UA113317C2/uk unknown
-
2015
- 2015-01-29 IL IL236981A patent/IL236981B/en unknown
- 2015-02-02 PH PH12015500231A patent/PH12015500231A1/en unknown
- 2015-02-03 CL CL2015000259A patent/CL2015000259A1/es unknown
- 2015-02-26 MA MA37870A patent/MA37870B1/fr unknown
- 2015-03-02 ZA ZA2015/01426A patent/ZA201501426B/en unknown
-
2022
- 2022-04-07 CY CY20221100263T patent/CY1125157T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125157T1 (el) | Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CY1121858T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων | |
| CY1124926T1 (el) | Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1123649T1 (el) | Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| CY1120673T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
| CY1123033T1 (el) | Σπειροκυκλικοι αναστολεις της καθεψινης c | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| CY1118416T1 (el) | Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| CY1117986T1 (el) | Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου | |
| CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
| MX374513B (es) | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. | |
| DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
| CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| CY1123056T1 (el) | Νεα μορφη χορηγησης της ρασεκαδοτριλης | |
| ECSP17057131A (es) | Desacetoxitubulisina h y análogos de esta | |
| CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos |